A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer
Clinical trial NCT04951635 · RECRUITING
Trial details
- NCT number
- NCT04951635
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-18
- Primary completion
- 2024-07-15
- Enrollment
- 150
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.